Full Name
Laurence Baril
Hospital/Organisation/Company
Takeda
Speaker Bio
I currently serve as Head of Epidemiology (since November 1st, 2023) within the Global Clinical
Development Department of the Vaccines Business Unit at Takeda Pharmaceuticals, based in Zurich,
Switzerland.
I am a medical doctor specialized in internal medicine, infectious diseases, and tropical medicine, with
extensive clinical experience. My academic background also includes a Master of Public Health (Clinical
Research option) and a PhD in Clinical Vaccinology and Pharmaco-Epidemiology.
My career spans diverse environments, including the private sector (Sanofi-Pasteur, GSK Vaccines), notfor-profit organizations (Pasteur Network based in African and Asian countries), and public institutions (French Ministry of Health, French Ministry of Foreign Affairs). Most recently, I worked at the French Medicines Agency (ANSM), where I contributed to the COVID-19 response and strengthened a dedicated unit of clinical and pharmacovigilance assessors for anti-infectives and vaccines.
Throughout my career, I have been deeply engaged in advancing global health, particularly through
infectious disease emergency responses and vaccine development in the context of post-approval
studies, leveraging my leadership experience across both health and research sectors.
Development Department of the Vaccines Business Unit at Takeda Pharmaceuticals, based in Zurich,
Switzerland.
I am a medical doctor specialized in internal medicine, infectious diseases, and tropical medicine, with
extensive clinical experience. My academic background also includes a Master of Public Health (Clinical
Research option) and a PhD in Clinical Vaccinology and Pharmaco-Epidemiology.
My career spans diverse environments, including the private sector (Sanofi-Pasteur, GSK Vaccines), notfor-profit organizations (Pasteur Network based in African and Asian countries), and public institutions (French Ministry of Health, French Ministry of Foreign Affairs). Most recently, I worked at the French Medicines Agency (ANSM), where I contributed to the COVID-19 response and strengthened a dedicated unit of clinical and pharmacovigilance assessors for anti-infectives and vaccines.
Throughout my career, I have been deeply engaged in advancing global health, particularly through
infectious disease emergency responses and vaccine development in the context of post-approval
studies, leveraging my leadership experience across both health and research sectors.
